Capital Performance Advisors’s CorMedix CRMD Stock Holding History

Capital Performance Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-47	Closed	-$380	–	740
2024 Q3	$380	Buy	+47	New	+$254	﹤0.01%	2370

Other funds holding CRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Performance Advisors's CRMD Position: Q4 2024 in Review

Capital Performance Advisors sold out of CorMedix (CRMD) in Q4 2024, closing a stake of 47 shares — an estimated $380 sold.

Capital Performance Advisors first reported a position in CRMD in Q3 2024 and held it in 1 quarter. The position peaked at $380 in Q3 2024. 129 funds tracked by Wall St. Rank hold CRMD as of Q4 2024.

Capital Performance Advisors reported no remaining CorMedix position as of Q4 2024 after selling out during the quarter.
Capital Performance Advisors sold 47 CorMedix shares in Q4 2024, an estimated $380.
Capital Performance Advisors first reported a position in CorMedix in Q3 2024 and held it in 1 quarter.
Capital Performance Advisors's CorMedix position peaked at $380 in Q3 2024.
129 funds tracked by Wall St. Rank held CorMedix as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.